AstraZeneca joins stepped-up antibiotic R&D action with FOB Synthesis deal

Tracy Staton

notched an antibiotics research with a licensing/option set-up with FOB , covering combinations of the two companies' experimental drugs.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS